A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor
Launched by HOFFMANN-LA ROCHE · Mar 4, 2014
Trial Information
Current as of May 14, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • adult patients, 18-75 years of age;
- • rheumatoid arthritis for \>=6 months;
- • previous inadequate response to a single anti-TNF alpha inhibitor;
- • methotrexate at a stable dose range 7.5-25 mg/week.
- Exclusion Criteria:
- • other chronic inflammatory articular disease or systemic autoimmune disease;
- • previous treatment with MabThera or intolerance to MabThera;
- • corticosteroids\>=10 mg/day prednisolone within last 2 weeks, or corticosteroids at unstable doses within last 2 weeks;
About Hoffmann La Roche
Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Freiburg, , Germany
Oldenburg, , Germany
Berlin, , Germany
Frankfurt Am Main, , Germany
Hannover, , Germany
Erlangen, , Germany
Halle, , Germany
Tübingen, , Germany
Homburg/Saar, , Germany
Heidelberg, , Germany
Wuerzburg, , Germany
Ulm, , Germany
Gommern, , Germany
Herne, , Germany
Köln, , Germany
Bad Bramstedt, , Germany
Essen, , Germany
München, , Germany
Osnabrück, , Germany
Sendenhorst, , Germany
Stuttgart, , Germany
Münster, , Germany
Hofheim, , Germany
Jena, , Germany
Ratingen, , Germany
Mönchengladbach, , Germany
Erfurt, , Germany
Muenchen, , Germany
Göttingen, , Germany
Ludwigshafen, , Germany
Trier, , Germany
Hamburg, , Germany
Rostock, , Germany
Wuppertal, , Germany
Treuenbrietzen, , Germany
Bad Abbach, , Germany
Zeven, , Germany
Bonn, , Germany
Bad Aibling, , Germany
Düsseldorf, , Germany
Pirna, , Germany
Bremen, , Germany
Cuxhaven, , Germany
Damp, , Germany
Donaueschingen, , Germany
Dresden, , Germany
Fulda, , Germany
Hagen, , Germany
Mainz, , Germany
Naunhof, , Germany
Wiesbaden, , Germany
Würselen, , Germany
Karlsruhe, , Germany
Bamberg, , Germany
Gießen, , Germany
Mittelherwigsdorf, , Germany
Schwerte, , Germany
Patients applied
Trial Officials
Clinical Trials
Study Chair
Hoffmann-La Roche
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials